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Purpose of study
Concerns exist regarding the central nervous system
(CNS) penetration and cognitive sequelae when utilising
novel, nucleoside-sparing treatment strategies such as
protease-inhibitor monotherapy.
Methods
The aim of this study was to assess changes to cerebral
function parameters in HIV-1 infected subjects, stable
on antiretroviral therapy with a plasma HIV RNA<50
copies/mL, randomised to commence on a one to one
basis, either darunavir/ritonavir (800/100 mg one daily)
alone (DRVmono) or with nucleoside analogues
(DRVnrti), within the MONET study. Cerebral function
was assessed via a detailed, validated, computerised neu-
rocognitive function assessment (CogState™)a n dc e r e -
bral metabolites measured via cerebral proton
spectroscopy in three anatomical locations (frontal grey
and white matter and right basal ganglia (RBG)), at
baseline and after 48 weeks. Associations between cere-
bral function parameters and study treatment arms were
evaluated using linear regression.
Results
6 subjects were enrolled (3 assigned to each treatment
arm) with a mean age of 44 years (SD 4.5) and 83%
male. Mean baseline plasma CD4+ cell count was 503
cells/uL (SD 173). Over 48 weeks, mean score improve-
ments were observed in 6 of 8 neurocognitive tasks
assessed including speed domains (2.5% increase identi-
fication speed), accuracy domains (4.6% increase non-
visual learning) and executive function (30% reduction
in errors). Reductions in cerebral metabolite markers of
cerebral inflammation (choline:creatine (Cr) and myo-
inositol:Cr ratios) were also observed in all cerebral
locations assessed (maximum reduction of 28% myo-
inositol:Cr ratio in frontal grey matter). No associations
between study treatment arm and these improvements
in cerebral function parameters were observed (p>0.06
all values).
Conclusion
On detailed assessment of cerebral function, overall
improvements were observed over 48 weeks in subjects
allocated to either DRVmono or DRVnrti. Despite very
small numbers, our study highlights future tools which
can practically be utilised to assess cerebral function in
HIV-treatment programmes.
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